Newsroom

Sorted by: Latest
-

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate du...
-

Orca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio today announced new data presented on its lead investigational allogeneic T-cell immunotherapy, Orca-T, at the 67th ASH Annual Meeting....
-

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from two ongoing clinical trials evaluating the efficacy and safety of epcoritamab-bysp, a T-cell engaging antibody administered subcutaneously, as a monotherapy and in combination with other standard of care treatments in adult patients with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Results from two arms of the EPCORE® NHL-2 trial, evaluating first-line, fixed-treatment dur...
-

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. The results were presented by Ionis Pharmaceuticals...
-

NMDP℠ Demonstrates Scientific Leadership in Expanding Patient Access to Lifesaving Cell Therapy at ASH 2025

MINNEAPOLIS--(BUSINESS WIRE)--New research from NMDP, a global nonprofit leader in cell therapy, and conducted by CIBMTR® (Center for International Blood and Marrow Transplant Research®) at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Fla., demonstrates that patients receiving allogeneic transplantation using more deeply mismatched unrelated donors (MMUD), followed by post-transplant chemotherapy, can achieve outcomes comparable to those receiving tran...
-

ReAlta Announces Promising Phase 2 Data Demonstrating Rapid Clinical Responses and Target Engagement in Steroid-Refractory Acute GvHD at the ASH 2025 Annual Meeting

NORFOLK, Va.--(BUSINESS WIRE)--ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company dedicated to saving lives by rebalancing the inflammatory response to address rare and acute inflammatory diseases, today announced a presentation of interim Phase 2 clinical data on RLS-0071 (pegtarazimod) for the treatment of acute graft-versus-host disease (aGvHD) at the 67th American Society of Hematology (ASH) Annual Meeting. The new findings will be presented i...
-

Genetix Participates in the American Society of Hematology’s (ASH) Exclusive Press Program & Shares Recent Patient Experience Data from U.S. Commercial Gene Therapy Implementation

SOMERVILLE, Mass.--(BUSINESS WIRE)--Genetix Biotherapeutics Inc. today announced their participation in the American Society of Hematology’s (ASH) exclusive press program ahead of the 67th ASH annual meeting in Orlando, Florida (December 6-9, 2025). Genetix’s abstract Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia was selected by the ASH Program Committee as one of the meeting’s most impactful datasets sub...
-

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with seve...
-

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies

TENGCHONG, China--(BUSINESS WIRE)--The 2025 Tengchong Scientists Forum opened on 6th December, 2025 in southwest China’s Yunnan Province....
-

Lattice wint Global Semiconductor Alliance Award 2025

HILLSBORO, Ore.--(BUSINESS WIRE)--Lattice Semiconductor (NASDAQ: LSCC), marktleider op het gebied van programmeerbare laagvermogens, heeft vandaag bekendgemaakt dat het is geselecteerd als 'Meest gerespecteerde beursgenoteerde halfgeleideronderneming' tijdens de Global Semiconductor Alliance (GSA) Awards 2025. De GSA Awards belonen bedrijven die uitmuntende prestaties hebben geleverd door hun succes, visie, strategie en toekomstige kansen in de branche, zoals bepaald door de stemmen van GSA-led...